The PE Ratio as of September 2024 (TTM) for Cullinan Oncology, Inc. (CGEM) is -5.88

According to Cullinan Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.88. This represents a change of 33.37% compared to the average of -4.41 of the last 4 quarters.

Cullinan Oncology, Inc. (CGEM) Historical PE Ratio (quarterly & annually)

How has CGEM PE Ratio performed in the past?

The mean historical PE Ratio of Cullinan Oncology, Inc. over the last ten years is -20.61. The current -5.88 PE Ratio has changed 2.75% with respect to the historical average. Over the past ten years (40 quarters), CGEM's PE Ratio was at its highest in in the June 2022 quarter at 0.82. The PE Ratio was at its lowest in in the March 2021 quarter at -6247.13.

Cullinan Oncology, Inc. (CGEM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cullinan Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cullinan Oncology, Inc. (CGEM) Average PE Ratio

How has CGEM PE Ratio performed in the past?

The current PE Ratio of Cullinan Oncology, Inc. (CGEM) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cullinan Oncology, Inc. (CGEM) PE Ratio vs. Peers

How is CGEM’s PE Ratio compared to its peers?

Cullinan Oncology, Inc.’s PE Ratio is less than Bolt Biotherapeutics, Inc. (-0.37), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Lyra Therapeutics, Inc. (-0.18), less than Autolus Therapeutics plc (-4.55), less than Sana Biotechnology, Inc. (-4.82), greater than Olema Pharmaceuticals, Inc. (-6.07), less than aTyr Pharma, Inc. (-2.33), less than Zentalis Pharmaceuticals, Inc. (-1.08), less than Century Therapeutics, Inc. (-0.91), greater than Edgewise Therapeutics, Inc. (-14.14), less than C4 Therapeutics, Inc. (-3.44), less than Mineralys Therapeutics, Inc. (-4.63), less than Talaris Therapeutics, Inc. (-0.20), less than Adicet Bio, Inc. (-0.98), less than Vor Biopharma Inc. (-0.53), less than Lyell Immunopharma, Inc. (-1.42), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Theseus Pharmaceuticals, Inc. (-3.19), greater than Revolution Medicines, Inc. (-13.31),

Build a custom stock screener for Cullinan Oncology, Inc. (CGEM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cullinan Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cullinan Oncology, Inc. (CGEM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cullinan Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.